QSAM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
QSAM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, QSAM Biosciences's enterprise value is $36.03 Mil. QSAM Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.00 Mil. Therefore, QSAM Biosciences's EV-to-EBITDA for today is -9.02.
The historical rank and industry rank for QSAM Biosciences's EV-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest EV-to-EBITDA of QSAM Biosciences was 8.93. The lowest was -311.06. And the median was -2.07.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-06-14), QSAM Biosciences's stock price is $16600.00. QSAM Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3560.000. Therefore, QSAM Biosciences's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for QSAM Biosciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
QSAM Biosciences Annual Data | |||||||||||||||||||||
Trend | Mar14 | Mar15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | -41.68 | -3.03 | -1.04 | -1.94 | -5.29 |
QSAM Biosciences Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EV-to-EBITDA | Get a 7-Day Free Trial | -1.94 | -2.40 | -3.13 | -3.71 | -5.29 |
For the Biotechnology subindustry, QSAM Biosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, QSAM Biosciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where QSAM Biosciences's EV-to-EBITDA falls into.
QSAM Biosciences's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 36.028 | / | -3.995 | |
= | -9.02 |
QSAM Biosciences's current Enterprise Value is $36.03 Mil.
QSAM Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
QSAM Biosciences (OTCPK:QSAM) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
QSAM Biosciences's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 16600.00 | / | -3560.000 | |
= | At Loss |
QSAM Biosciences's share price for today is $16600.00.
QSAM Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3560.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of QSAM Biosciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Adam King | officer: Chief Financial Officer | 9442 CAPITAL OF TEXAS HWY N, PLAZA 1, SUITE 500, AUSTIN TX 78759 |
Link Jr. Charles J | director | C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AIMES IA 50010 |
Adriann Sax | director | 7 DORSET COURT,, EAST BRUNSWICK, NJ 08816 |
David Charles Link | director | 2100 E 54TH STREET NORTH, SIOUX FALLS SD 57104 |
Douglas R Baum | director, officer: CEO & Director | 5000 RAFFEE COVE, AUSTIN TX 78731-1132 |
C Richard Piazza | director, officer: Executive Chairman | 2236 EAST MALL, SUITE 208, UNIVERSITY OF BRITISH COLUMBIA, VANCOUVER A1 V6T 1Z3 |
Checkmate Strategic Capital Holdings, Llc | other: Member of 13(d) 10% owner grp | 595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101 |
Checkmate Strategic Capital 2, Llc | 10 percent owner, other: See Explanation of Responses | 595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101 |
Checkmate Capital Group, Llc | 10 percent owner, other: Member of 13(d) 10% owner grp | 595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101 |
Charles Thomas Paschall | other: Member of 13(d) 10% owner grp | 595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101 |
Christopher M. Nelson | director, officer: General Counsel | 420 ROYAL PALM WAY, SUITE #100, PALM BEACH FL 33480 |
Scott W. Whitney | director, other: Former Director | 96 WINDSOR DRIVE, PINE BROOK NJ 07058 |
Kevin Bolin | director, officer: Former Chairman & CEO | 1081 ROSEDALE DRIVE, ATLANTA GA 30306 |
Tristan Peitz | director, other: Former Director | C/O Q2POWER TECHNOLOGIES, INC., 420 ROYAL PALM WAY, #100, PALM BEACH FL 33480 |
Joel David Mayersohn | director | 350 EAST LAS OLAS BLVD. #1150, FORT LAUDERDALE FL 33301 |
From GuruFocus
By Marketwired Marketwired • 08-18-2021
By sperokesalga sperokesalga • 02-28-2023
By Marketwired Marketwired • 01-28-2021
By sperokesalga sperokesalga • 05-23-2023
By Marketwired Marketwired • 05-25-2021
By Stock market mentor Stock market mentor • 01-10-2023
By sperokesalga sperokesalga • 04-26-2023
By GuruFocusNews GuruFocusNews • 01-25-2022
By Marketwired Marketwired • 04-28-2021
By sperokesalga sperokesalga • 05-16-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.